Typically, PD-L1 expression, tumor mutational burden and tumor infiltrating T cells are shown to be predictive of patient outcomes, but these markers are used only for reference in the clinic due to their insufficient sensitivity and specificity19–23. The gene discussed is CD274; the disease is neoplasm.